BRPI1008752A2 - compostos alquilamido e usos dos mesmos - Google Patents

compostos alquilamido e usos dos mesmos

Info

Publication number
BRPI1008752A2
BRPI1008752A2 BRPI1008752A BRPI1008752A BRPI1008752A2 BR PI1008752 A2 BRPI1008752 A2 BR PI1008752A2 BR PI1008752 A BRPI1008752 A BR PI1008752A BR PI1008752 A BRPI1008752 A BR PI1008752A BR PI1008752 A2 BRPI1008752 A2 BR PI1008752A2
Authority
BR
Brazil
Prior art keywords
starch compounds
alkyl starch
alkyl
compounds
starch
Prior art date
Application number
BRPI1008752A
Other languages
English (en)
Inventor
Francesca Viti
Salvatore Bellinvia
Sergio Baroni
Original Assignee
Giuliani Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Giuliani Int Ltd filed Critical Giuliani Int Ltd
Publication of BRPI1008752A2 publication Critical patent/BRPI1008752A2/pt
Publication of BRPI1008752B1 publication Critical patent/BRPI1008752B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/008—Preparations for oily skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A61Q7/02—Preparations for inhibiting or slowing hair growth
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/53—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/54—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/38—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/08—1,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
BRPI1008752-4A 2009-02-16 2010-02-16 Compostos alquilamido, composições farmacêuticas e usos dos mesmos BRPI1008752B1 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP09425056.0 2009-02-16
EP09425056 2009-02-16
US17906209P 2009-05-18 2009-05-18
US61/179.062 2009-05-18
US28746109P 2009-12-17 2009-12-17
US61/287.461 2009-12-17
PCT/EP2010/000935 WO2010091892A2 (en) 2009-02-16 2010-02-16 Alkylamido compounds and uses thereof

Publications (2)

Publication Number Publication Date
BRPI1008752A2 true BRPI1008752A2 (pt) 2016-03-08
BRPI1008752B1 BRPI1008752B1 (pt) 2020-02-11

Family

ID=42562114

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI1008752-4A BRPI1008752B1 (pt) 2009-02-16 2010-02-16 Compostos alquilamido, composições farmacêuticas e usos dos mesmos
BRPI1011226-0A BRPI1011226B1 (pt) 2009-02-16 2010-02-16 uso de uma composição farmacêutica para tratar condições relacionadas ao cabelo

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI1011226-0A BRPI1011226B1 (pt) 2009-02-16 2010-02-16 uso de uma composição farmacêutica para tratar condições relacionadas ao cabelo

Country Status (25)

Country Link
US (11) US8754127B2 (pt)
EP (4) EP2396081B1 (pt)
JP (4) JP5715070B2 (pt)
KR (2) KR101776337B1 (pt)
CN (3) CN102316931B (pt)
AR (1) AR080596A1 (pt)
AU (2) AU2010213095B2 (pt)
BR (2) BRPI1008752B1 (pt)
CA (2) CA2752626C (pt)
CY (2) CY1119225T1 (pt)
DK (2) DK2805746T3 (pt)
EA (2) EA020856B1 (pt)
ES (3) ES2429143T3 (pt)
HR (2) HRP20170936T1 (pt)
HU (2) HUE032999T2 (pt)
IL (2) IL214665A (pt)
LT (2) LT2396081T (pt)
MX (3) MX2011008602A (pt)
NZ (2) NZ595080A (pt)
PL (1) PL2396081T3 (pt)
PT (3) PT2396081T (pt)
SI (2) SI2396081T1 (pt)
UA (2) UA105037C2 (pt)
WO (2) WO2010091892A2 (pt)
ZA (1) ZA201106256B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4805556A (en) 1988-01-15 1989-02-21 Union Carbide Corporation Reactor system and method for forming uniformly large-diameter polycrystalline rods by the pyrolysis of silane
ITRM20050390A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
ITRM20050389A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
UA107562C2 (uk) 2008-12-05 2015-01-26 Спосіб лікування псоріазу
HRP20170936T1 (hr) 2009-02-16 2017-09-22 Nogra Pharma Limited Alkilamido spojevi i njihova uporaba
JP2014511393A (ja) * 2011-03-07 2014-05-15 セルジーン コーポレイション イソインドリン化合物を用いた疾患の治療方法
WO2013117744A2 (en) * 2012-02-09 2013-08-15 Nogra Pharma Limited Methods of treating fibrosis
NZ631049A (en) 2012-04-18 2017-02-24 Nogra Pharma Ltd Methods of treating lactose intolerance
AU2013314288B2 (en) * 2012-09-13 2018-07-05 Nogra Pharma Limited Methods of treating hair related conditions
JP2015528480A (ja) * 2012-09-13 2015-09-28 ノグラ ファーマ リミテッド 毛の成長の阻害方法
KR101441278B1 (ko) * 2013-11-17 2014-09-17 한규나 머리카락 분말을 이용한 재활용 방법
JP6371520B2 (ja) * 2013-12-26 2018-08-08 日本メナード化粧品株式会社 皮脂合成促進剤
CN107613971A (zh) 2015-04-06 2018-01-19 宾夕法尼亚大学董事会 用于减少、或预防或逆转哺乳动物对象中皮肤色素沉着增加的组合物和方法
WO2017210600A1 (en) * 2016-06-03 2017-12-07 The Scripps Research Institute Compositions and methods of modulating immune response
EP3914227A1 (en) * 2019-01-25 2021-12-01 Nogra Pharma Limited Compositions for use in preventing acne
AU2020217884B2 (en) * 2019-02-08 2025-02-20 Nogra Pharma Limited Process of making 3-(4'-aminophenyl)-2-methoxypropionic acid, and analogs and intermediates thereof
JP6925072B1 (ja) * 2020-12-07 2021-08-25 株式会社Dr.Cherry 毛髪改善のための組成物

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB767788A (en) * 1953-12-28 1957-02-06 Schering Corp Polyiodinated phenyl fatty acid compounds and process for their manufacture
US3211610A (en) 1961-09-29 1965-10-12 Merck & Co Inc Benzoic acid ester derivatives for treating coccidiosis and method of using same
US3444232A (en) 1966-05-18 1969-05-13 Squibb & Sons Inc O-alkyl or phenylalkyl benzohydroxamic acids
GB1359560A (en) 1972-02-25 1974-07-10 Merck & Co Inc Preparation of pyrrylsalicylic acid
US4036951A (en) 1973-03-12 1977-07-19 Synergistics, Inc. Ultra-violet filtration with certain aminosalicylic acid esters
FR2440353A1 (fr) 1978-11-03 1980-05-30 Science Union & Cie Nouveaux arylethanols, leurs procedes d'obtention et leur emploi comme medicament
US4348223A (en) 1980-12-05 1982-09-07 Ppg Industries, Inc. N-Alkyl-N-[3-(alkoxyalkyl)phenyl]-2-haloacetamide herbicides
DE3164618D1 (en) 1980-12-22 1984-08-09 Schering Ag 3-substituted 2,4,6-trihalogenobenzamides and their salts, their preparation and their use as substitutes for natural sweetening agents, and sweeteners containing them
JPS58194814A (ja) 1982-05-11 1983-11-12 Nippon Shinyaku Co Ltd 免疫調節作用を有する薬剤
IL69282A (en) 1982-09-02 1988-06-30 Euro Celtique Sa Method for the carboxylation of potassium phenoxide with carbon dioxide
GB8302708D0 (en) 1983-02-01 1983-03-02 Efamol Ltd Pharmaceutical and dietary composition
EP0279096B1 (en) 1987-02-05 1993-07-07 Kureha Kagaku Kogyo Kabushiki Kaisha Benzyl ether compound and process for producing the same
US4933330A (en) * 1987-04-01 1990-06-12 Dak-Laboratoriet Benzoic acid derivatives and use thereof
DE68919009T2 (de) 1988-05-05 1995-02-23 Tillotts Pharma Ag Verwendung von 5-Amino-salicylsäure für die Behandlung von Hautkrankheiten.
US5519014A (en) 1990-10-22 1996-05-21 Borody; Thomas J. Treatment of non-inflammatory and non-infectious bowel disorders
WO1992006690A1 (en) 1990-10-22 1992-04-30 Borody Thomas J Treatment of non-inflammatory and non-infectious bowel disorders
US5262549A (en) 1991-05-30 1993-11-16 Polaroid Corporation Benzpyrylium dyes, and processes for their preparation and use
WO1993019053A1 (en) 1992-03-17 1993-09-30 Fujisawa Pharmaceutical Co., Ltd. Depsipeptide derivative, production thereof and use thereof
US5302751A (en) 1992-01-21 1994-04-12 Ethyl Corporation Profen resolution
DE69331727D1 (de) 1992-06-30 2002-04-25 Howard K Shapiro Verwendung einer kombination bestehend aus einem aminderivat oder aminverwandten derivat der benzoesäure und einem amino-polysaccharide zur herstellung eines medikaments fuer die behandlung von entzündlichen erkrankungen
US5594151A (en) 1994-01-28 1997-01-14 Prolinx, Inc. Phenylboronic acid complexing reagents derived from aminosalicylic acid
CA2190107A1 (en) 1994-05-11 1995-11-23 Secant Pharma, Llc Compositions for treatment of chronic inflammatory diseases
US5594015A (en) 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
JPH10511097A (ja) 1995-03-28 1998-10-27 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 低薬用量リドグレル調合物および炎症性腸疾患の処置のためのそれらの使用
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9617001D0 (en) 1996-08-13 1996-09-25 Tillotts Pharma Ag Oral composition
DE19647582A1 (de) 1996-11-18 1998-05-20 Hoechst Ag Verfahren zur Herstellung von aromatischen Olefinen mittels Katalyse durch Palladaphosphacyclobutane
AU6773598A (en) 1997-03-26 1998-10-20 Institut Pasteur Treatment of gastrointestinal disease with ppar modulators
WO1999005161A1 (en) 1997-07-25 1999-02-04 Ligand Pharmaceuticals Incorporated HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA (PPARη) GENE REGULATORY SEQUENCES AND USES THEREFOR
AU9002798A (en) 1997-09-19 1999-04-12 Ono Pharmaceutical Co. Ltd. Fused or nonfused benzene compounds
US7015249B1 (en) 1997-12-12 2006-03-21 Purdue Research Foundation Methods and compositions for treating diabetes
FR2773075B1 (fr) 1997-12-31 2000-05-05 Cird Galderma Utilisation d'activateurs de ppar-gamma en dermatologie
US6114382A (en) 1998-11-11 2000-09-05 Moretti; Itagiba G. Methods for treating inflammatory bowel disease
US6326364B1 (en) 1999-02-08 2001-12-04 Cedars-Sinai Medical Center Use of 5-aminosalicylates as antimicrobial agents
FR2791671B1 (fr) 1999-04-01 2001-05-11 Oreal Nouveaux composes derives d'esters d'acide benzoique, composition les comprenant et utilisation
GB9908647D0 (en) 1999-04-15 1999-06-09 Smithkline Beecham Plc Novel compounds
US20040034067A1 (en) 1999-04-15 2004-02-19 Macphee Colin Houston Novel method of treatment
GB9914371D0 (en) 1999-06-18 1999-08-18 Smithkline Beecham Plc Novel compounds
TWI262185B (en) 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
WO2001025226A1 (en) 1999-10-05 2001-04-12 Bethesda Pharmaceuticals, Inc. Dithiolane derivatives
US7736661B1 (en) 2000-03-07 2010-06-15 Avon Products, Inc Method of treating skin conditions
CN1267408C (zh) 2000-04-19 2006-08-02 纽若泰克有限公司 预防中枢神经系统急慢性损伤中神经变性的化合物,组合物和方法
US7049342B2 (en) 2000-05-29 2006-05-23 Kyorin Pharmaceutical Co., Ltd. Substituted phenylpropionic acid derivatives
SI1285908T1 (sl) * 2000-05-29 2008-12-31 Kyorin Seiyaku Kk Substituirani fenilpropionski kislinski derivati
AU8531101A (en) 2000-08-29 2002-03-13 Nobex Corp Immunoregulatory compounds and derivatives and methods of treating diseases therewith
EP1348698A4 (en) 2000-12-05 2005-01-19 Kyorin Seiyaku Kk SUBSTITUTED CARBOXYLENE DERIVATIVES
FR2822955B1 (fr) 2001-03-27 2003-10-03 Chru Lille Methode de diagnostic de maladies inflammatoires chroniques de l'intestin
US7312247B2 (en) 2001-03-27 2007-12-25 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
EP1389044A4 (en) 2001-04-18 2006-07-05 Merck & Co Inc PPAR ALPHA GAMMA LIGANDS OR AGONISTS FOR THE TREATMENT OF INFLAMMATION
CA2354921A1 (en) 2001-05-24 2002-11-24 Yasuo Konishi Drug evolution: drug design at hot spots
PL369732A1 (en) 2001-10-16 2005-05-02 Dr.Reddy's Laboratories Ltd. Benzoxazine and benzothiazine derivatives and pharmaceutical compositions containing them
WO2003043569A2 (en) 2001-11-16 2003-05-30 Nutrition 21, Inc. Trans-10, cis-12 conjugated linoleic acid isomer for the treatment of diseases
GB0127916D0 (en) 2001-11-21 2002-01-16 Rowett Res Inst Method
EP1465622A1 (en) 2001-11-26 2004-10-13 Arachnova Therapeutics Ltd. Use of ppar activators for the treatment of pulmonary fibrosis
UA82835C2 (en) * 2001-12-03 2008-05-26 Reddys Lab Ltd Dr ?-aryl-?-oxysubstituted propionuc acid derivatives and pharmaceutical composition based thereon
US20030113815A1 (en) 2001-12-19 2003-06-19 Pfizer Inc. Canine peroxisome proliferator activated receptor gamma
WO2003053974A1 (en) 2001-12-21 2003-07-03 Dr. Reddy's Laboratories Ltd. Novel compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
US20030220374A1 (en) 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
US20040115127A1 (en) 2002-04-12 2004-06-17 Wright Samuel D. Ppar-alpha-gamma ligands or agonists for the treatment of inflammation
US8492438B2 (en) 2002-04-26 2013-07-23 Asan Laboratories Company (Cayman), Limited Treatment skin disorders
AU2003228744A1 (en) 2002-04-29 2003-11-17 The Ohio State University Inhibition of protein tyrosine phosphatases and sh2 domains by a neutral phosphotyrosine mimetic
DE10250080A1 (de) 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
GB0303609D0 (en) 2003-02-17 2003-03-19 Glaxo Group Ltd Novel therapeutic method and compositions
US20060159648A1 (en) 2003-02-17 2006-07-20 Davis Adrian F Novel therapeutic method and compositions for topical administration
US20060177444A1 (en) 2003-03-20 2006-08-10 Tatsuo Horizoe Concomitant drug as therapeutic agent for inflammatory bowel disease
ATE455772T1 (de) 2003-07-21 2010-02-15 Merck Serono Sa Alkinylarylcarbonsäureamide
UA60954C2 (en) 2003-07-25 2006-03-15 Subsidiary Entpr With Foreign Method for measuring conductivity of electrolyte by a contactless measuring transducer
JP2007509180A (ja) 2003-10-21 2007-04-12 インスパイアー ファーマシューティカルズ，インコーポレイティド 疼痛を治療するための、非ヌクレオチド組成物および方法
WO2005040102A2 (en) 2003-10-28 2005-05-06 Dr. Reddy's Laboratories Ltd. Novel compounds and their use as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them
FR2862870A1 (fr) 2003-12-01 2005-06-03 Galderma Res & Dev Utilisation d'activateurs de recepteurs ppar en cosmetique et dermatologie.
EP1691806A2 (en) 2003-12-03 2006-08-23 Smithkline Beecham Corporation Novel therapeutic method and compositions
EP1722630A4 (en) 2004-01-20 2009-05-27 Richard F Harty COMPOSITIONS AND METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES
WO2005084658A1 (en) 2004-03-04 2005-09-15 Arakis Ltd. Derivatives of actarit and their therapeutic use
US20050277693A1 (en) 2004-06-10 2005-12-15 Dr. Reddy's Laboratories Limited Basic salts and monohydrates of certain alpha, beta-propionic acid derivative
GT200500246A (es) 2004-09-09 2006-04-17 Combinacion de compuestos organicos
US20100041617A1 (en) 2004-09-27 2010-02-18 Jane Trepel Modulating mxa expression
US20060286046A1 (en) 2005-01-05 2006-12-21 Haber C Andrew Skin care compositions
EP1719543A1 (en) 2005-05-04 2006-11-08 Asan Labs., Ltd. Use of histone deacetylase inhibitors for the treatment of gastrointestinal distress
US20060270635A1 (en) 2005-05-27 2006-11-30 Wallace John L Derivatives of 4- or 5-aminosalicylic acid
ITRM20050390A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
ITRM20050389A1 (it) * 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
DE102005061472A1 (de) 2005-12-22 2007-07-05 Saltigo Gmbh Verfahren zur Herstellung von enantiomerenangereicherten 2-Alkoxy-3-phenylpropionsäuren
WO2007096148A1 (en) 2006-02-23 2007-08-30 Lipid Nutrition B.V. Immunoregulation
US7645801B2 (en) 2007-01-29 2010-01-12 Alaven Pharmaceutical Llc Reduced irritant enema for treatment of inflammatory bowel disease (IBD)
IE20070129A1 (en) 2007-02-28 2008-12-24 Giuliani Int Ltd Ppar-gamma agonists stimulate enteric defensin expression
US8796282B2 (en) 2007-03-28 2014-08-05 Case Western Reserve University Method of treating dermatological disorders
WO2009025854A1 (en) 2007-08-22 2009-02-26 Burnham Institute For Medical Research Smips: small molecule inhibitors of p27 depletion in cancers and other proliferative diseases
ITMI20072429A1 (it) 2007-12-24 2009-06-25 Giuliani Int Ltd Composti per il trattamento selettivo della componente immuno-infiammatoria intestinale della malattia celiaca
US8030520B2 (en) 2008-03-31 2011-10-04 Saltigo Gmbh Process for preparing organic compounds by a transition metal-catalysed cross-coupling reaction of an aryl-X, heteroaryl-X, cycloalkenyl-X or alkenyl-X compound with an alkyl, alkenyl, cycloalkyl or cycloalkenyl halide
UA107562C2 (uk) 2008-12-05 2015-01-26 Спосіб лікування псоріазу
HRP20170936T1 (hr) 2009-02-16 2017-09-22 Nogra Pharma Limited Alkilamido spojevi i njihova uporaba
EP2298321A1 (en) 2009-08-26 2011-03-23 Nordic Pharma Novel pharmaceutical compositions for treating IBD
CA2841358A1 (en) 2011-07-15 2013-01-24 S.L.A. Pharma Ag Pharmaceutical compositions for rectal administration
MX351878B (es) 2011-10-17 2017-11-01 The Regents Of Univ Of California Metodos para evaluar la calidad del repelente de materiales organicos y metodos y composiciones para repeler artropodos.
US9809557B2 (en) 2011-10-31 2017-11-07 Claus Selch Larsen Prodrugs of non-steroid anti-inflammatory agents (NSAIDS)
WO2013117744A2 (en) 2012-02-09 2013-08-15 Nogra Pharma Limited Methods of treating fibrosis
NZ631049A (en) 2012-04-18 2017-02-24 Nogra Pharma Ltd Methods of treating lactose intolerance
JP6096179B2 (ja) 2012-05-10 2017-03-15 国立大学法人岩手大学 ラクターゼ活性を有するタンパク質、該タンパク質をコードする遺伝子、該遺伝子を含有する組み換えベクター、形質転換体、及びその製造方法並びに用途
US9013997B2 (en) 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
KR20150016377A (ko) 2012-06-01 2015-02-11 노그라 파마 리미티드 T-세포 반응을 조절할 수 있는 비시클릭 헤테로사이클 및 그의 사용 방법
CN104870438A (zh) 2012-06-07 2015-08-26 佐治亚州立大学研究基金会公司 Seca抑制剂以及其制备和使用方法
JP2015528480A (ja) 2012-09-13 2015-09-28 ノグラ ファーマ リミテッド 毛の成長の阻害方法
AU2013314288B2 (en) 2012-09-13 2018-07-05 Nogra Pharma Limited Methods of treating hair related conditions
US20160045523A1 (en) 2013-03-26 2016-02-18 Lipid Therapeutics Gmbh Pharmaceutical formulation comprising phosphatidylcholine for the treatment of ulcerative colitis
CN105566153B (zh) 2014-10-14 2019-05-31 中国医学科学院药物研究所 偶氮苯衍生物及其制法和药物组合物与用途
US20180193361A1 (en) 2015-04-02 2018-07-12 University Health Network Gut anti-inflammatory agents for regulation of high blood glucose levels
DK3307262T3 (da) 2015-06-15 2021-08-09 Nmd Pharma As Forbindelser til anvendelse ved behandling af neuromuskulære lidelser
WO2017046343A1 (en) 2015-09-17 2017-03-23 Nogra Pharma Limited Compositions for rectal administration in the treatment of ulcerative colitis and methods of using same
WO2017093444A1 (en) 2015-12-01 2017-06-08 Nogra Pharma Limited Compositions for oral administration in the treatment of inflammatory bowel disease
MA43682A (fr) 2016-02-26 2018-11-28 Nogra Pharma Ltd Procédés de traitement de l'intolérance au lactose

Also Published As

Publication number Publication date
MX381002B (es) 2025-03-12
JP2012517969A (ja) 2012-08-09
IL214664A0 (en) 2011-09-27
EP2396081A2 (en) 2011-12-21
EP2805746B1 (en) 2020-05-06
PT2396082E (pt) 2013-10-03
EA201171062A1 (ru) 2012-01-30
DK2396081T3 (en) 2017-07-10
JP5645851B2 (ja) 2014-12-24
EP2396081B1 (en) 2017-04-05
MX2011008601A (es) 2011-09-09
EP2396082A2 (en) 2011-12-21
US20180369178A1 (en) 2018-12-27
US20150051285A1 (en) 2015-02-19
AR080596A1 (es) 2012-04-25
US20220354809A1 (en) 2022-11-10
KR101800901B1 (ko) 2017-11-23
SI2805746T1 (sl) 2020-10-30
US20120053245A1 (en) 2012-03-01
EA020198B1 (ru) 2014-09-30
CN102316931B (zh) 2014-11-19
US9901557B2 (en) 2018-02-27
ES2429143T3 (es) 2013-11-13
AU2010213093A1 (en) 2011-09-08
BRPI1008752B1 (pt) 2020-02-11
US20160338927A1 (en) 2016-11-24
US10137101B2 (en) 2018-11-27
EA020856B1 (ru) 2015-02-27
JP5820030B2 (ja) 2015-11-24
MX2011008602A (es) 2011-09-09
WO2010091894A3 (en) 2010-11-11
US20150148418A1 (en) 2015-05-28
IL214665A0 (en) 2011-09-27
HUE050267T2 (hu) 2020-11-30
KR101776337B1 (ko) 2017-09-07
NZ595076A (en) 2013-09-27
AU2010213095B2 (en) 2015-09-17
AU2010213093B2 (en) 2016-01-07
EA201171063A1 (ru) 2012-01-30
KR20110120946A (ko) 2011-11-04
KR20110120945A (ko) 2011-11-04
CY1119225T1 (el) 2018-02-14
EP2396082B1 (en) 2013-07-31
CA2752626C (en) 2018-03-27
AU2010213095A1 (en) 2011-09-08
CN102316931A (zh) 2012-01-11
BRPI1011226B1 (pt) 2019-10-29
PL2396081T3 (pl) 2017-10-31
JP2012517968A (ja) 2012-08-09
US20190269637A1 (en) 2019-09-05
WO2010091894A2 (en) 2010-08-19
IL214665A (en) 2017-02-28
WO2010091892A3 (en) 2010-10-21
US8754127B2 (en) 2014-06-17
SI2396081T1 (sl) 2017-09-29
US20200188340A1 (en) 2020-06-18
PT2396081T (pt) 2017-07-11
JP2014237692A (ja) 2014-12-18
PT2805746T (pt) 2020-08-17
ZA201106256B (en) 2012-05-30
JP2015155427A (ja) 2015-08-27
BRPI1011226A2 (pt) 2016-03-15
CA2752623A1 (en) 2010-08-19
HUE032999T2 (hu) 2017-11-28
HRP20170936T1 (hr) 2017-09-22
CN104666288A (zh) 2015-06-03
LT2805746T (lt) 2020-09-25
CN102316932B (zh) 2014-07-09
US10959970B2 (en) 2021-03-30
LT2396081T (lt) 2017-09-11
JP5715070B2 (ja) 2015-05-07
CA2752623C (en) 2017-07-04
HRP20201184T1 (hr) 2020-12-11
ES2630044T3 (es) 2017-08-17
ES2806691T3 (es) 2021-02-18
CN102316932A (zh) 2012-01-11
NZ595080A (en) 2013-09-27
IL214664A (en) 2015-09-24
EP3744398A1 (en) 2020-12-02
US9511041B2 (en) 2016-12-06
CN104666288B (zh) 2017-08-04
UA105037C2 (uk) 2014-04-10
US8796334B2 (en) 2014-08-05
CY1123213T1 (el) 2021-12-31
US20170172956A1 (en) 2017-06-22
EP2805746A1 (en) 2014-11-26
US10398667B2 (en) 2019-09-03
CA2752626A1 (en) 2010-08-19
WO2010091892A2 (en) 2010-08-19
US20120053244A1 (en) 2012-03-01
US20200383942A1 (en) 2020-12-10
DK2805746T3 (da) 2020-08-10
UA109525C2 (xx) 2015-09-10

Similar Documents

Publication Publication Date Title
BRPI1008752A2 (pt) compostos alquilamido e usos dos mesmos
BR112012003709A2 (pt) compostos heterocíclicos e usos dos mesmos
BRPI1014997A2 (pt) compostos heteroarila e usos dos mesmos
BRPI0908906A2 (pt) compostos heterocíclicos e usos dos mesmos
BRPI0914682A2 (pt) compostos de heteroarila e usos dos mesmos
BRPI0920927A2 (pt) derivados de azaquinolinona e usos dos mesmos
BRPI1009455A2 (pt) anticorpos anti-c40 e usos dos mesmos
BRPI1013943A2 (pt) Composto cetais e usos dos mesmos.
HRP20151000T8 (hr) Antivirusni spojevi
BRPI1013246A2 (pt) derivados de benzofuralina
BR112012002828A2 (pt) derivados de 5-fluorpirimidinona
BR112012005438A2 (pt) inibidores de vírus flaviviridae
DK2397480T3 (da) Diazepindionderivat
BRPI1013844A2 (pt) derivados de piridina-isoxazol
BR112012010242A2 (pt) derivados de heteroarilpiperidina e heteroarilpiperazina
BRPI1014454A2 (pt) derivados de isoxazol-pirazol
DK2387580T3 (da) Deoxyactagardinderivater
BR112012002810A2 (pt) derivados de n1-acil-5-fluoropirimidinona
PT2492266E (pt) Derivado de 5-hidroxipirimidino-4-carboxamida
CU23884B1 (es) Derivados de dibenzotiazepina
EP2242714A4 (en) Protective insert
DK2173197T3 (da) Fremgangsmåde
BR112013014190A2 (pt) derivados de nitróxido multifuncionais e usos dos mesmos
DK2405910T3 (da) Rosuvastatin- og atorvastatinderivater
BR112012003603A2 (pt) [4-(5-aminometil-fenil)-piperidin-1il]-1hindol-3-il]-metanonas dissubstituídas

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: NOGRA PHARMA LIMITED (IE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/02/2010, OBSERVADAS AS CONDICOES LEGAIS.